Comparative Pharmacology
Head-to-head clinical analysis: CARDIZEM SR versus CARTIA XT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIZEM SR versus CARTIA XT.
CARDIZEM SR vs CARTIA XT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cells during depolarization, leading to vasodilation and reduced myocardial contractility and conduction velocity, particularly at the AV node.
Oral: Initial dose 60-120 mg twice daily; titrate to maximum 360 mg/day divided into two doses.
Diltiazem hydrochloride extended-release capsules (CARTIA XT) are administered orally. For hypertension and angina, the typical adult dose is 180–360 mg once daily, initially 180 mg once daily, titrated to response.
None Documented
None Documented
3.0-4.5 hours for diltiazem; metabolites (e.g., desacetyldiltiazem) up to 10 hours. Clinical context: dosing interval adjustment in hepatic impairment.
Terminal half-life 3-4.5 hours; prolonged in hepatic impairment (up to 15 hours) or with cimetidine.
Renal: 2-4% unchanged; hepatic metabolism: ~60-70% (including active metabolites); fecal: ~30-40%.
Renal (biliary/fecal minimal). 70-80% excreted as inactive metabolites in urine; 15% unchanged.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker